Key points are not available for this paper at this time.
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Caroline Robert
Jacob Schachter
Georgina V. Long
New England Journal of Medicine
University of California, Los Angeles
University of California, San Francisco
University of Manchester
Building similarity graph...
Analyzing shared references across papers
Loading...
Robert et al. (Sun,) studied this question.
www.synapsesocial.com/papers/6916108be621bd59682e6e1a — DOI: https://doi.org/10.1056/nejmoa1503093